

Daftar Pustaka

- Abisheganaden, J., Verma ,A., Dagaonkar, R.S., Light, R.W., 2018. An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore. *Respiration* 96: 308-313.
- Adzic, T.N., Pesut, D.P., Nagorni-Obradovic, L.M., Stojsic, J.M., Vasiljevic, M.D., Bouros, D., 2008. Clinical features of lung cancer in patients with connective tissue diseases: a 10-year hospital based study. *Respir Med*;102:620–624.
- Agalioti, T., Giannou, A.D., Krontira, A.C., Kanellakis, N.I., Kati, D., Vreka, *et al.*, 2017. Mutant KRAS promotes malignant pleural effusion formation. *Nat. Commun.*, 8, 15205.
- Amin, Z., Iskandar, S.D., Sibli., 2017. Prognostic Factors of 30-day Survival of Patients with Malignant Pleural Effusion. *Indian J Palliat Care*. 23: 321-24.
- Anevlavis, S., Kouliatsis, G., Sotiriou, I., Koukourakis, M.I., *et al.*, 2014. Prognostic Factors in Patients Presenting with Pleural Effusion Revealing Malignancy. *Respiration* 87:311–316.
- American Thoracic Society, 2000. Management of Malignant Pleural Effusions. *Am J Respir Crit Care Med* 162 (5) :1987–2001.
- Awadallah, S.F., Bowling, M.R., Sharma, N., Mohan, A., 2019. Malignant pleural effusion and cancer of unknown primary site: a review of literature. *Ann Transl Med* 7(15): 353.
- Azam, F., Latif , M.F., Farooq, A., Tirmazy, S.H., *et al.*, 2019. Performance status assessmen by using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Heatlhcare Profesionals. *Case Rep Oncol* 12: 728-36.
- Belle, S.J., Cocquyt, V., 2003. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. *Crit Rev Oncol Hematol*, 47 (1): 1-11.
- Bibby, A.C., Dorn, P., Psallidas, I., *et al.*, 2018. ERS/EACTS statement on the management of malignant pleural effusions. *Eur Respir J* 52: 1800349 .
- Burrows, C.M., Mathews, W.C., Colt, H.G., 2000. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. *Chest* 117: 73-8.
- Caro, J.J., Salas, M., Ward, A., Goss, G., 2001. Anemia as an independent prognostic factor for survival in patients with cancer: A systematic, quantitative review. *Cancer*, volume 91, 12: 2214-21.
- Chan, J.N., Villalon, J., 2017. Prognostic utility of the LENT score in predicting survival among patients with malignant pleural effusion admitted at the Chinese General Hospital and Medical Center. *Respirology* 22 (suppl.3) : 88-278.
- Charalampidis, C., Youroukou, A., Lazaridis, G., Baka, S., Karavasilis, V., Kioumis I, *et al.*, 2015. Physiology of the pleural space. *J. Thorac. Dis.* 7 :33–37.

- Chen, Y., Mathy, N.W., Lu, H., 2018. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (review). *Mol. Med. Rep.* 17: 8019–8030.
- Clive, A.O., Kahan, B.C., Hooper, C.E., Bhatnagar, R., Morley, A.J., Zahan-Evans, N. *et al.*, 2014. Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score. *Thorax* 69: 1098–1104.
- Clive, A.O., Jones, H.E., Bhatnagar, R., Preston, N.J., Maskell, N., 2016. Interventions for the management of malignant pleural effusions: a network meta-analysis. *Cochrane Database Syst Rev* (5): CD010529.
- Dahlan, M.S., 2011. *Penelitian Prognostik dan Sistem Skoring: disertai Praktik dengan SPSS dan Stata*. Seri Evidence Based Medicine (Seri 8). Alqaprint Jatinangor, Bandung.
- Desai, N.R., Lee, H.J., 2017. Diagnosis and management of malignant pleural effusions: state of the art in 2017. *J Thorac Dis* 9 (Suppl 10): S1111-S1122.
- Dipper, A., Maskell, N., 2020. Prognostication in malignant pleural effusion: One size does not fit all. *Respirology* 25: 1229–1230.
- Feller-Kopman, D., Walkey, A., Berkowitz, D., *et al.* 2006. The relationship of pleural pressure to symptom development during therapeutic thoracentesis. *Chest* 129: 1556-60.
- Fogar, P., Sperti, C., Basso, D., Sanzari, M.C., Greco, E., Davoli, C., *et al.*, 2006. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. *Pancreas* 32: 22–28.
- Giannou, A.D., Marazioti, A., Spella, M, Kanellakis, N.I, Apostolopoulou, H., Psallidas, I., *et al.*, 2015. Mast cells mediate malignant pleural effusion formation. *J. Clin. Investig.*, 125: 2317–2334.
- Globocan, 2020. International Agency to Research on Cancer, WHO. Indonesia. The Global Cancer Observatory. Available from URL: <https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf>
- Gondhowiardjo, S., Handoyo, D., Auzan, M., Sekarutami, S.M., Christina, N., *et al.*, 2018. Cancer Profile in West Jakarta: A 5-year descriptive study. *Radioterapi & Onkologi Indonesia* 9 (2): 43-47.
- Good, J.T., Taryle, D.A., Maulitz, R.M., Kaplan, R.L., *et al.*, 1980. The diagnostic value of pleura fluid pH. *Chest* 78 (1):55-9.
- Good, J.T., Taryle, D.A., Sahn, S.A., 1985. The pathogenesis of low glucose, low pH malignant effusions. *Am Rev Respir Dis.* 131(5): 737-41.
- Grecian, R., Whyte, M.K.B., Walmsley, S.R., 2018. The role of neutrophils in cancer. Invited review. *British Medical Bulletin* 128 : 5-14.
- Heffner, J.E., Nietert, P.J., Barbieri, C., 2000. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. *Chest* 117:79-86.
- Ingelfinger, J.R., Feller-Kopman, D., Light, R., 2018. Pleural disease. *N. Engl. J. Med.* 378: 740–751.
- Jeba, J., Cherian, R.M., Visalakshi, J., 2018. Prognostic Factors of Malignant Pleural Effusion among Palliative Care Outpatients : A retrospective study. *Indian J Palliative Care.* 24 (2): 184-88.

- Johnston, W.W., 1985. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. *Cancer* 56: 905-9.
- Krochmal, R., Reddy, C., Yarmus, L., *et al.*, 2016. Patient evaluation for rapid pleurodesis of malignant pleural effusions. *J Thorac Dis* 8:2538-43.
- Lee, Y.S., Nam, H.S., Lee, H.L., *et al.*, 2017. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients. *BMC Cancer* 17:557.
- Lepus, C.M., Vivero, M., 2018. Updates in Effusion Cytology. *Surg. Pathol. Clin.* 11: 523–544.
- Leung, A.N., Muller, N.L., Miller, R.R., 1990. CT in differential diagnosis of diffuse pleural disease. *AJR Am J Roentgenol* 154: 487–492.
- Lissoni, P., Brivio, F., Fumagalli, L., Messina, G., Ghezzi, V., Frontini, L., Giani, L., Vaghi, M., Ar- dizzoia, A., Gardani, G.S., 2004. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. *Int J Biol Markers* 19:135–140.
- Martínez-Moragón, E., Aparicio, J., Sanchis, J., Menéndez, R., Cruz-Rogado, M., Sanchis, F., 1998. Malignant pleural effusion: Prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. *Respiration* 65:108–13.
- Menzies, R., Charbonneau, M., 1991. Thoracoscopy for the diagnosis of pleural disease. *Ann Intern Med* 114: 271–276.
- Nuranna, L., Fahrudin, A., 2019. Survival Rate of Cervical Cancer in National Referral Hospital in 2012-2014. *Acta Medica Indonesiana-Indonesian Journal of Internal Medicine* 51 (2).
- Paesmans, M., Sculier, J. P., Libert, P., Bureau, G., Dabouis, G., Thiriaux, J., Michel, J., Van Cutsem, O., Sergysels, R., Mommen, P., *et al.* 1995. Prognostic factors for survival in advanced non-small- cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients – the European Lung Cancer Working Party. *J Clin Oncol* 13:1221–1230.
- Psallidas, I., Kalomenidis, I., Porcel, J.M., Robinson, B.W., Stathopoulos, G.T., 2016. Malignant pleural effusion: From bench to bedside. *Eur. Respir. Rev.* 25: 189–198.
- Penz, E., Watt, K.N., Hergot, C.A., *et al.*, 2017. Management of malignant pleural effusion: challenges and solutions. *Cancer Management and Research* 9: 229–241.
- Porcel, J.M., Solé, C., Salud, A., Bielsa, S., 2017. Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion. *Lung* 195: 775–779.
- Quek, J.C., Tan, Q.L., Allen, J.C., Anantham, D., 2020. Malignant pleural effusion survival prognostication in an Asian population. *Respirology* 25(12): 1283–91.
- Rivera, M.P., 2019. Management of Malignant Pleural Effusions: Round dan Round We Go. *Annals ATS* 16 : 11.

- Roberts, M.E., Neville, E., Berrisford, R.G., *et al.* 2010. Management of a malignant pleural effusion: British Thoracic Society, 21. Pleural Disease Guideline 2010. *Thorax* 65 Suppl 2: 32-40.
- Rodriguez-Panadero, F., Janssen, J.P., Astoul, P., 2006. Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion. *Eur Respir J* 28:409–422.
- Sahn, S.A., 1997. Pleural diseases related to metastatic malignancies. *Eur Respir J* 10:1907–1901.
- Sahn, S.A., Good, J.T.Jr., 1988. Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. *Ann Intern Med* 108:345-9.
- Sarraf, K.M., Belcher, E., Raevsky, E., Nicholson, A.G., Goldstraw, P., Lim, E., 2009. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. *J Thorac Cardiovasc Surg* 137: 425–428.
- Schiller, J.H., Harrington, D., Belani, C.P., 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *The New England Journal of Medicine* 346 (2): 92-8.
- Schmidt, H., Bastholt, L., Geertsen, P., Christensen, I.J., Larsen, S., Gehl, J., von der Maase, H., 2005. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. *Br J Cancer* 93:273– 278.
- Sculier, J.P., Chansky, K., Crowley, J.J., Van Meer-beeck J., Goldstraw, P., 2008. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. *J Thorac Oncol* 3:457–466.
- Sinaga, E.S., Ahmad, R.A., Shivalli, S., Hutajulu, S.H., 2018. Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia. *Pan Afr Med J* 31:163
- Skok, K., Hladnik, G., Grm, A., Arnjac, A., 2019. Review Malignant Pleural Effusion and Its Current Management: A Review. *Medicina* 55: 490 doi:10.3390/medicina55080490
- Shojaee, S., Voelkel, N., Farkas, L., *et al.*, 2013. Transforming growth factor-beta1 rise in pleural fluid after tunneled pleural catheter placement: pilot study. *J Bronchology Interv Pulmonol* 20:304-8.
- Soogard, M., Thomsen, R.W., Norgard, M., 2013. The impact of commorbidity on cancer survival: a review. *Clin Epidemiol*, 5(suppl 1):3-29.
- Van Meter, M.E., McKee, K.Y., Kohlwes, R.J., 2011. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. *J Gen Intern Med* 26:70-6.
- Verma, A., Phua, C.K., Abisheganaden, J., 2016. Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion. *Medicine (Baltimore)* 95(26):e3996.

- Walker-Renard, P.B., Vaughan, L.M., Sahn, S.A., 1994. Chemical pleurodesis for malignant pleural effusions. *Ann Intern Med* 120:56-64.
- Warren, W.H., Kalimi, R., Khodadadian, L.M., *et al.*, 2008. Management of malignant pleural effusions using the Pleural catheter. *Ann Thorac Surg* 85:1049-55.
- Yalcin, N.G., Choong, C.K.C., Eizenberg, N., 2013. Anatomy and Pathophysiology of the Pleura and Pleural Space. *Thorac. Surg. Clin.* 23 :1–10.
- Zamboni, M.M., da Silva, C.T., Cardoso, G.P., 2015. Important prognostic factors for survival in patients with malignant pleural effusion. *BMC Pulmonary Medicine*; 15:29.